- Home
- CRBU vs CNTN Comparison
CRBU vs CNTN Comparison
Compare CRBU & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBU | CNTN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.9M | 176.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CRBU | CNTN |
|---|---|---|
| Price | $1.75 | $4.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 644.8K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $4.44 |
| 52 Week High | $3.53 | $5.27 |
Technical Indicators
Market Signals| Indicator | CRBU | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 39.71 |
| Support Level | $1.71 | N/A |
| Resistance Level | $2.11 | $5.27 |
| Average True Range (ATR) | 0.15 | 0.44 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 36.00 | 20.61 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.